Due to global asthma prevalence, asthma product sales are rising. City living, pollution, and lifestyle changes are causing more lung diseases. This increases the requirement for asthma control equipment.
New innovations are transforming the asthma device industry, notably breathing equipment. Smart inhalers with sensors and connections are becoming increasingly prevalent. These provide patients real-time feedback on their inhalation and medication compliance. Doctors can better manage illnesses and treat patients using this technology.
Digital asthma management alternatives are growing in popularity. Personalized treatment plans, remote monitoring, and teleconsultations are being offered via mobile applications, EHRs, and telemedicine platforms. This makes patients more engaged in and committed to therapy.
Kids' asthma care is getting more attention, and age-appropriate, easy-to-use asthma products are being developed. Youth asthma management is made simpler and more exciting with easy-to-use inhalers, colored spacers, and game-like mobile applications.
Biologics and targeted asthma therapies are popular. These devices-based therapies target asthma inflammatory mechanisms. This provides severe asthmatics more effective and tailored options.
Asthma devices are increasingly integrating environmental monitoring functions. These devices can monitor air quality, pollen, and other asthma triggers. These devices notify users about their environment to prevent asthma attacks.
Patient-centered and easy-to-use asthma products are growing in popularity. To help patients self-administer, inhalers and other devices are being designed with ergonomic design, easy-to-read dosage indicators, and auditory cues.
Partnerships between medicine firms, device producers, and healthcare personnel affect the asthma goods industry. Global agreements and alliances strive to simplify product development and distribution so more individuals can use better asthma control methods.
Portable nebulizers are popular since they're simple to use and effective for asthmatics. These portable devices provide asthmatics who require regular or emergency treatments greater freedom and flexibility.
Despite advancements, breathing equipment is still hard to obtain, particularly in low-income communities. Education, cost reduction, and worldwide partnerships strive to narrow these gaps and make asthma management measures more accessible.
Asthma Devices Market Size was valued at USD 4.00 Billion in 2023. The Global Asthma Devices industry is projected to grow from USD 4.21 Billion in 2024 to USD 7.45 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.89% during the forecast period (2024 - 2032).Asthma is a chronic inflammatory lung disease that narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Mostly, the symptoms associated with asthma are short-lived and can be easily treated. Asthma inhalers are medical devices which deliver medication into the body via the lungs, thereby, treating asthma and chronic obstructive pulmonary disease. Increasing prevalence of asthma is one of the major drivers for the market growth.
The UK-based medical device company Acurable disclosed this in October 2022, saying it was helped to raise $10.8 million by its lead investor for the round, Kibo Ventures. The firm will use the funding to speed up AcuPebble SA100, which is a home-based sleep diagnostic tool that helps identify and track obstructive sleep apnea cases around the world. Moreover, Acurable would develop new drugs for cardiovascular diseases, asthma and COPD.
Adherium Limited has partnered with Trudell Medical Limited in August 2022 to treat U.S. patients with COPD.
A US$350 million Series A funding round was won by Arteria Therapeutics, a biotechnology company committed to helping asthmatics live normal lives in July of 2022. This money was expected by the company to fund phase 3 trials for a new asthma candidate that is said to have biologic-like efficacy in treating asthma through oral delivery.
Alkem launched Innohaler, a DPI device in March 2022 with an aim of improving comfort living for Asthma and COPD (Chronic Obstructive Pulmonary Disease) patients and narrowing the existing gaps in Asthma care across India. The introduction of this device marks Alkem’s entry into core inhalation treatments where it expects better medication will reach the lungs with every inhalation due to increased patient awareness and adherence program.
Life Wellness Healthcare announced an update on their online store that allows individuals with chronic obstructive pulmonary disease (COPD) be able to reduce their symptoms at home as of January 2022. Payment plans are available when purchasing AirPhysio devices, which are now ready for shipment throughout the United States.
For example, in March 2022, the US Food and Drug Administration approved Symbicort Inhalation Aerosol’s first generic version for treating two common pulmonary conditions, including asthma, among six-year-old and older patients.
For example, a Phase III clinical trial evaluating budesonide/glycopyrronium/formoterol inhalers effectiveness and safety among adults and adolescents who suffer from severe asthma and are inadequately controlled with the standard of care was initiated in March 2021 by AstraZeneca PLC in Mexico and the United States. The trial is expected to be completed in September 2023.
The global asthma devices market is segmented on the basis of type, technology, and end users.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)